Eisai's Fycompa falls at German HTA comparator hurdle, like GSK's Trobalt
This article was originally published in Scrip
Comparator issues that proved troublesome for GlaxoSmithKline's antiepileptic Trobalt (retigabine) in Germany are now causing problems for Eisai's own antiepileptic Fycompa (perampanel). IQWiG, the body that carries out the preliminary scientific assessment for Germany's AMNOG early benefit assessments, said that Eisai's drug offers no additional benefit over comparators because it did not submit any relevant data lamotrigine or topiramate.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.